Adaptive Biotechnologies (ADPT) Invested Capital (2018 - 2026)

Adaptive Biotechnologies has disclosed Invested Capital across 9 years of filings, most recently posting $222.1 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $222.1 million, up 15.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $222.1 million (up 15.56% YoY), and the FY2025 annual result was $223.4 million, up 9.88% from the prior year.
• Invested Capital came in at $222.1 million for Q1 2026 at Adaptive Biotechnologies, down from $223.4 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $553.3 million in Q1 2022 to a low of $182.6 million in Q2 2025.
• The 5-year median for Invested Capital is $274.8 million (2024), against an average of $322.8 million.
• Across the five-year window, Invested Capital slumped 39.03% in 2024 and grew 15.56% in 2026, its largest moves.
• Adaptive Biotechnologies' Invested Capital stood at $464.1 million in 2022, then slumped by 33.57% to $308.3 million in 2023, then sank by 34.04% to $203.4 million in 2024, then grew by 9.88% to $223.4 million in 2025, then slipped by 0.58% to $222.1 million in 2026.
• The last three Invested Capital figures came in at $222.1 million (Q1 2026), $223.4 million (Q4 2025), and $206.9 million (Q3 2025), per Business Quant data.